Pacira Pharma (PCRX) Tops Q3 EPS by 17c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'
November 9, 2017 9:56 AM ESTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from $38.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.
Analyst Gary Nachman notes a positive outlook on the shares, as the company reported earnings per share... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies
November 9, 2017 8:29 AM ESTJefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $52.00 (from $57.00) while maintaining a Buy rating following results.
Analyst David Steinberg trimmed FY17 Exparel revs by $8M to $283M to align with the midpoint of updated guidance.They also trim FY18-20 sales ests by 4-6%
... More